Last reviewed · How we verify
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.
Details
| Lead sponsor | Beijing Peking University WBL Biotech Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 116 |
| Start date | 2011-04 |
| Completion | 2012-12 |
Conditions
- Hyperlipidemia
Interventions
- XueZhiKang (XZK), a botanic product with multiple components
- Placebo
Primary outcomes
- Mean percentage change from baseline at week 12 (or the last assessment) on serum low-density lipoprotein cholesterol (LDL-C) level. — Screening, Baseline, Week 4, Week 6, and Week 12
Countries
United States, China